The incidence of psychotic disorders among migrants and minority ethnic groups in Europe: findings from the multinational EU-GEI study.


Journal

Psychological medicine
ISSN: 1469-8978
Titre abrégé: Psychol Med
Pays: England
ID NLM: 1254142

Informations de publication

Date de publication:
05 2022
Historique:
pubmed: 23 9 2020
medline: 3 6 2022
entrez: 22 9 2020
Statut: ppublish

Résumé

In Europe, the incidence of psychotic disorder is high in certain migrant and minority ethnic groups (hence: 'minorities'). However, it is unknown how the incidence pattern for these groups varies within this continent. Our objective was to compare, across sites in France, Italy, Spain, the UK and the Netherlands, the incidence rates for minorities and the incidence rate ratios (IRRs, minorities v. the local reference population). The European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) study was conducted between 2010 and 2015. We analyzed data on incident cases of non-organic psychosis (International Classification of Diseases, 10th edition, codes F20-F33) from 13 sites. The standardized incidence rates for minorities, combined into one category, varied from 12.2 in Valencia to 82.5 per 100 000 in Paris. These rates were generally high at sites with high rates for the reference population, and low at sites with low rates for the reference population. IRRs for minorities (combined into one category) varied from 0.70 (95% CI 0.32-1.53) in Valencia to 2.47 (95% CI 1.66-3.69) in Paris (test for interaction: p = 0.031). At most sites, IRRs were higher for persons from non-Western countries than for those from Western countries, with the highest IRRs for individuals from sub-Saharan Africa (adjusted IRR = 3.23, 95% CI 2.66-3.93). Incidence rates vary by region of origin, region of destination and their combination. This suggests that they are strongly influenced by the social context.

Sections du résumé

BACKGROUND
In Europe, the incidence of psychotic disorder is high in certain migrant and minority ethnic groups (hence: 'minorities'). However, it is unknown how the incidence pattern for these groups varies within this continent. Our objective was to compare, across sites in France, Italy, Spain, the UK and the Netherlands, the incidence rates for minorities and the incidence rate ratios (IRRs, minorities v. the local reference population).
METHODS
The European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) study was conducted between 2010 and 2015. We analyzed data on incident cases of non-organic psychosis (International Classification of Diseases, 10th edition, codes F20-F33) from 13 sites.
RESULTS
The standardized incidence rates for minorities, combined into one category, varied from 12.2 in Valencia to 82.5 per 100 000 in Paris. These rates were generally high at sites with high rates for the reference population, and low at sites with low rates for the reference population. IRRs for minorities (combined into one category) varied from 0.70 (95% CI 0.32-1.53) in Valencia to 2.47 (95% CI 1.66-3.69) in Paris (test for interaction: p = 0.031). At most sites, IRRs were higher for persons from non-Western countries than for those from Western countries, with the highest IRRs for individuals from sub-Saharan Africa (adjusted IRR = 3.23, 95% CI 2.66-3.93).
CONCLUSIONS
Incidence rates vary by region of origin, region of destination and their combination. This suggests that they are strongly influenced by the social context.

Identifiants

pubmed: 32958094
doi: 10.1017/S0033291720003219
pii: S0033291720003219
pmc: PMC9157293
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1376-1385

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 101272/Z/13/Z
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom

Références

Br J Psychiatry. 2005 Jan;186:74-5
pubmed: 15630127
Psychol Med. 2019 Oct;49(14):2354-2363
pubmed: 30514409
Lancet Psychiatry. 2016 Sep;3(9):832-41
pubmed: 27528097
Eur Psychiatry. 2008 Jan;23 Suppl 1:14-20
pubmed: 18371575
J Nerv Ment Dis. 1985 Oct;173(10):577-81
pubmed: 3875685
Schizophr Bull. 2017 Mar 1;43(2):293-301
pubmed: 28057720
Br J Psychiatry. 2011 Aug;199(2):151-5
pubmed: 21804150
Psychol Med. 2021 Jul;51(9):1536-1548
pubmed: 32122439
Schizophr Bull. 2017 Jan 3;43(2):287-292
pubmed: 28053019
JAMA Psychiatry. 2018 Jan 1;75(1):36-46
pubmed: 29214289
JAMA Psychiatry. 2014 Dec 1;71(12):1364-72
pubmed: 25271822
Schizophr Bull. 2013 Nov;39(6):1180-6
pubmed: 24062592
Lancet Public Health. 2019 May;4(5):e229-e244
pubmed: 31054641
Br J Psychiatry. 1996 Nov;169(5):587-92
pubmed: 8932887
Psychol Med. 2011 May;41(5):897-910
pubmed: 20663257
Psychol Med. 2020 Jan;50(2):303-313
pubmed: 30722795
Soc Psychiatry Psychiatr Epidemiol. 2014 Jul;49(7):1161-74
pubmed: 24213521
World Psychiatry. 2019 Oct;18(3):247-258
pubmed: 31496097
Am J Psychiatry. 2005 Jan;162(1):12-24
pubmed: 15625195
Schizophr Res. 2002 Apr 1;54(3):219-21
pubmed: 11950546
Am J Psychiatry. 2017 Feb 1;174(2):143-153
pubmed: 27771972
Soc Psychiatry Psychiatr Epidemiol. 2017 Feb;52(2):147-154
pubmed: 27847980
Br J Psychiatry. 2005 Aug;187:101-2
pubmed: 16055818
Br J Psychiatry. 1999 Jul;175:28-33
pubmed: 10621765
Br J Psychiatry. 1995 Aug;167(2):193-6
pubmed: 7582668

Auteurs

Fabian Termorshuizen (F)

Rivierduinen Institute for Mental Health Care, Sandifortdreef 19, 2333 ZZ Leiden, The Netherlands.

Els van der Ven (E)

Mailman School of Public Health, Columbia University, New York City, USA.
Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, P.O. Box 616, 6200 MD Maastricht, The Netherlands.

Ilaria Tarricone (I)

Department of Medical and Surgical Science, Bologna Transcultural Psychosomatic Team (BoTPT), Alma Mater Studiorum Università di Bologna, Viale Pepoli 5, 40126 Bologna, Italy.
Department of Biomedical and Neuro-motor Sciences, Psychiatry Unit, Alma Mater Studiorum Università di Bologna, 40126 Bologna, Italy.

Hannah E Jongsma (HE)

Department of Psychiatry, University of Cambridge, Herchel Smith Building for Brain & Mind Sciences, Forvie Site, Robinson Way, Cambridge, CB2 0SZ, UK.
Psylife Group, Division of Psychiatry, University College London, 6th Floor, Maple House, 149 Tottenham Court Road, London, W1T 7NF, UK.

Charlotte Gayer-Anderson (C)

Department of Health Service and Population Research, Institute of Psychiatry, King's College London, De Crespigny Park, Denmark Hill, SE5 8AF, London, UK.

Antonio Lasalvia (A)

Section of Psychiatry, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.

Sarah Tosato (S)

Section of Psychiatry, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.

Diego Quattrone (D)

Department of Psychosis Studies, Institute of Psychiatry, King's College London, De Crespigny Park, Denmark Hill SE5 8AF, London, UK.

Caterina La Cascia (C)

Unit of Psychiatry, "P. Giaccone" General Hospital, Via G. La Loggia n.1, 90129 Palermo, Italy.

Andrei Szöke (A)

INSERM, U955, Equipe 15, 51 Avenue de Maréchal de Lattre de Tassigny, 94010 Créteil, France.

Domenico Berardi (D)

Department of Biomedical and Neuro-motor Sciences, Psychiatry Unit, Alma Mater Studiorum Università di Bologna, 40126 Bologna, Italy.

Pierre-Michel Llorca (PM)

CMPB CHU Clermont-Ferrand, EA 7280, University Clermont Auvergne, Clermont-Ferrand, France.

Lieuwe de Haan (L)

Department of Psychiatry, Early Psychosis Section, Amsterdam UMC, location AMC, University of Amsterdam, Meibergdreef 5, 1105 AZ Amsterdam, The Netherlands.

Eva Velthorst (E)

Department of Psychiatry and Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, USA.

Miguel Bernardo (M)

Barcelona Clinic Schizophrenia Unit, Neuroscience Institute, Hospital Clinic of Barcelona, Barcelona, Spain.
Department of Medicine, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain.

Julio Sanjuán (J)

Department of Psychiatry, School of Medicine, Universidad de Valencia, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), C/Avda. Blasco Ibáñez 15, 46010 Valencia, Spain.

Manuel Arrojo (M)

Department of Psychiatry, Psychiatry Genetic Group, Instituto de Investigación Sanitaria de Santiago de Compostela, Complejo Hospitalario Universitario de Santiago de Compostela, 15706 Santiago de Compostela, Spain.

Robin M Murray (RM)

Department of Psychosis Studies, Institute of Psychiatry, King's College London, De Crespigny Park, Denmark Hill SE5 8AF, London, UK.

Bart P Rutten (BP)

Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, P.O. Box 616, 6200 MD Maastricht, The Netherlands.

Peter B Jones (PB)

Department of Psychiatry, University of Cambridge, Herchel Smith Building for Brain & Mind Sciences, Forvie Site, Robinson Way, Cambridge, CB2 0SZ, UK.
CAMEO Early Intervention Service, Cambridgeshire & Peterborough NHS Foundation Trust, Cambridge, CB21 5EF, UK.

Jim van Os (J)

Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, P.O. Box 616, 6200 MD Maastricht, The Netherlands.
Department of Psychosis Studies, Institute of Psychiatry, King's College London, De Crespigny Park, Denmark Hill SE5 8AF, London, UK.
Department Psychiatry, Brain Center Rudolf Magnus, Utrecht University Medical Centre, Utrecht, The Netherlands.

James B Kirkbride (JB)

Psylife Group, Division of Psychiatry, University College London, 6th Floor, Maple House, 149 Tottenham Court Road, London, W1T 7NF, UK.

Craig Morgan (C)

Department of Health Service and Population Research, Institute of Psychiatry, King's College London, De Crespigny Park, Denmark Hill, SE5 8AF, London, UK.

Jean-Paul Selten (JP)

Rivierduinen Institute for Mental Health Care, Sandifortdreef 19, 2333 ZZ Leiden, The Netherlands.
Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, P.O. Box 616, 6200 MD Maastricht, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH